1887

Journal of General Virology header logo

Volume 103, Issue 8

Thermal stabilization of enterovirus A 71 and production of antigenically stabilized empty capsids Open Access

Abstract

Enterovirus A71 (EVA71) infection can result in paralysis and may be fatal. In common with other picornaviruses, empty capsids are produced alongside infectious virions during the viral lifecycle. These empty capsids are antigenically indistinguishable from infectious virus, but at moderate temperatures they are converted to an expanded conformation. In the closely related poliovirus, native and expanded antigenic forms of particle have different long-term protective efficacies when used as vaccines. The native form provides long-lived protective immunity, while expanded capsids fail to generate immunological protection. Whether this is true for EVA71 remains to be determined. Here, we selected an antigenically stable EVA71 virus population using successive rounds of heating and passage and characterized the antigenic conversion of both virions and empty capsids. The mutations identified within the heated passaged virus were dispersed across the capsid, including at key sites associated with particle expansion. The data presented here indicate that the mutant sequence may be a useful resource to address the importance of antigenic conformation in EVA71 vaccines.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): empty capsids , EVA71 , infantile paralysis and stabilization
Funding
This study was supported by the:
  • Saudi Arabia Cultural Bureau in London (Award x)
    • Principle Award Recipient: MonaShegdar
  • World Health Organization (Award 2019/883397-O)
    • Principle Award Recipient: HelenFox
  • Wellcome trust (Award 102174/B/13/Z)
    • Principle Award Recipient: S SnowdenJoseph
  • NIH (Award R01 AI 169457-0)
    • Principle Award Recipient: NicolaJ Stonehouse
  • NIH (Award R01 AI 169457-0)
    • Principle Award Recipient: DavidJ Rowlands
  • NIH (Award R01 AI 169457-0)
    • Principle Award Recipient: NatalieJ Kingston
  • Medical Research Council (Award MR/P022626/1)
    • Principle Award Recipient: DavidJ Rowlands
  • Medical Research Council (Award MR/P022626/1)
    • Principle Award Recipient: NicolaJ Stonehouse
  • Medical Research Council (Award MR/P022626/1)
    • Principle Award Recipient: AndrewMacadam
  • Wellcome Trust (Award 204825/Z/16/Z)
    • Principle Award Recipient: NatalieJ Kingston
© 2022 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001771
2022-08-23
2024-05-05
Loading full text...

Full text loading...

/deliver/fulltext/jgv/103/8/jgv001771.html?itemId=/content/journal/jgv/10.1099/jgv.0.001771&mimeType=html&fmt=ahah

References

  1. Ong KC, Wong KT. Understanding enterovirus 71 neuropathogenesis and its impact on other neurotropic enteroviruses. Brain Pathol 2015; 25:614–624 [View Article] [PubMed]
     [Google Scholar]
  2. Kapadia RK, Gill CM, Baca C, McMenamin C, Kannappan A et al. Enterovirus A71 causing meningoencephalitis and acute flaccid myelitis in a patient receiving rituximab. J Neuroimmunol 2021; 358:577639 [View Article] [PubMed]
     [Google Scholar]
  3. Aubart M, Gitiaux C, Roux CJ, Levy R, Schuffenecker I et al. Severe acute flaccid myelitis associated with enterovirus in children: two phenotypes for two evolution profiles?. Front Neurol 2020; 11:343 [View Article] [PubMed]
     [Google Scholar]
  4. Huang CC, Liu CC, Chang YC, Chen CY, Wang ST et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med 1999; 341:936–942 [View Article] [PubMed]
     [Google Scholar]
  5. Foo DGW, Alonso S, Chow VTK, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 2007; 9:1299–1306 [View Article] [PubMed]
     [Google Scholar]
  6. Foo DGW, Alonso S, Phoon MC, Ramachandran NP, Chow VTK et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 2007; 125:61–68 [View Article] [PubMed]
     [Google Scholar]
  7. Liu JN, Wang W, Duo JY, Hao Y, Ma CM et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 2010; 28:7444–7451 [View Article] [PubMed]
     [Google Scholar]
  8. Chung Y-C, Ho M-S, Wu J-C, Chen W-J, Huang J-H et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008; 26:1855–1862 [View Article] [PubMed]
     [Google Scholar]
  9. Zhang C, Ku Z, Liu Q, Wang X, Chen T et al. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine 2015; 33:2335–2341 [View Article] [PubMed]
     [Google Scholar]
  10. Li HY, Han JF, Qin CF, Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 2013; 31:3281–3287 [View Article] [PubMed]
     [Google Scholar]
  11. Puenpa J, Wanlapakorn N, Vongpunsawad S, Poovorawan Y. The history of enterovirus A71 outbreaks and molecular epidemiology in the asia-pacific region. J Biomed Sci 2019; 26:75 [View Article] [PubMed]
     [Google Scholar]
  12. Takahashi S, Liao Q, Van Boeckel TP, Xing W, Sun J et al. Hand, foot, and mouth disease in China: modeling epidemic dynamics of enterovirus serotypes and implications for vaccination. PLoS Med 2016; 13:e1001958 [View Article] [PubMed]
     [Google Scholar]
  13. Li R, Liu L, Mo Z, Wang X, Xia J et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014; 370:829–837 [View Article] [PubMed]
     [Google Scholar]
  14. Zhu F-C, Meng F-Y, Li J-X, Li X-L, Mao Q-Y et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013; 381:2024–2032 [View Article] [PubMed]
     [Google Scholar]
  15. World Health Organization Enterovirus 71; 2022 https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/enterovirus-71
  16. Mao Q, Wang Y, Bian L, Xu M, Liang Z. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microbes Infect 2016; 5:e75 [View Article] [PubMed]
     [Google Scholar]
  17. Du Z, Huang Y, Bloom MS, Zhang Z, Yang Z et al. Assessing the vaccine effectiveness for hand, foot, and mouth disease in Guangzhou, China: a time-series analysis. Hum Vaccin Immunother 2021; 17:217–223 [View Article] [PubMed]
     [Google Scholar]
  18. Hong J, Liu F, Qi H, Tu W, Ward MP et al. Changing epidemiology of hand, foot, and mouth disease in China, 2013-2019: a population-based study. Lancet Reg Health West Pac 2022; 20:100370 [View Article] [PubMed]
     [Google Scholar]
  19. Nathanson N, Langmuir AD. The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963. Am J Epidemiol 1995; 142:109–140 [View Article]
     [Google Scholar]
  20. Offit PA. The Cutter incident, 50 years later. N Engl J Med 2005; 352:1411–1412 [View Article] [PubMed]
     [Google Scholar]
  21. Dowdle WR, Wolff C, Sanders R, Lambert S, Best M. Will containment of wild poliovirus in laboratories and inactivated poliovirus vaccine production sites be effective for global certification?. Bull World Health Organ 2004; 82:59–62 [PubMed]
     [Google Scholar]
  22. Mulders MN, Reimerink JH, Koopmans MP, van Loon AM, van der Avoort HG. Genetic analysis of wild-type poliovirus importation into The Netherlands (1979-1995). J Infect Dis 1997; 176:617–624 [View Article] [PubMed]
     [Google Scholar]
  23. Deshpande JM, Nadkarni SS, Siddiqui ZA. Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003. Indian J Med Res 2003; 118:217–223 [PubMed]
     [Google Scholar]
  24. Duizer E, Rutjes S, de Roda Husman AM, Schijven J. Risk assessment, risk management and risk-based monitoring following a reported accidental release of poliovirus in Belgium, September to November 2014. Euro Surveill 2016; 21:30169 [View Article] [PubMed]
     [Google Scholar]
  25. Salmons B, Lim PY, Djurup R, Cardosa J. Non-clinical safety assessment of repeated intramuscular administration of an EV-A71 VLP vaccine in rabbits. Vaccine 2018; 36:6623–6630 [View Article] [PubMed]
     [Google Scholar]
  26. Wang X, Xiao X, Zhao M, Liu W, Pang L et al. EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge. BMC Res Notes 2016; 9:42 [View Article] [PubMed]
     [Google Scholar]
  27. Lyu K, He YL, Li HY, Chen R. Crystal structures of yeast-produced enterovirus 71 and enterovirus 71/Coxsackievirus A16 chimeric virus-like particles provide the structural basis for novel vaccine design against hand-foot-and-mouth disease. J Virol 2015; 89:6196–6208 [View Article] [PubMed]
     [Google Scholar]
  28. Gong M, Zhu H, Zhou J, Yang C, Feng J et al. Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development. J Virol 2014; 88:6444–6452 [View Article] [PubMed]
     [Google Scholar]
  29. Basavappa R, Syed R, Flore O, Icenogle JP, Filman DJ et al. Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 A resolution. Protein Sci 1994; 3:1651–1669 [View Article] [PubMed]
     [Google Scholar]
  30. Wang X, Peng W, Ren J, Hu Z, Xu J et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 2012; 19:424–429 [View Article] [PubMed]
     [Google Scholar]
  31. Miller ST, Hogle JM, Filman DJ. Ab initio phasing of high-symmetry macromolecular complexes: successful phasing of authentic poliovirus data to 3.0 A resolution. J Mol Biol 2001; 307:499–512 [View Article] [PubMed]
     [Google Scholar]
  32. Butan C, Filman DJ, Hogle JM. Cryo-electron microscopy reconstruction shows poliovirus 135S particles poised for membrane interaction and RNA release. J Virol 2014; 88:1758–1770 [View Article] [PubMed]
     [Google Scholar]
  33. Shah PNM, Filman DJ, Karunatilaka KS, Hesketh EL, Groppelli E et al. Cryo-EM structures reveal two distinct conformational states in a picornavirus cell entry intermediate. PLoS Pathog 2020; 16:e1008920 [View Article] [PubMed]
     [Google Scholar]
  34. Lyu K, Ding J, Han J-F, Zhang Y, Wu X-Y et al. Human enterovirus 71 uncoating captured at atomic resolution. J Virol 2014; 88:3114–3126 [View Article] [PubMed]
     [Google Scholar]
  35. Kingston NJ, Grehan K, Snowden JS, Shegdar M, Macadam AJ et al. Development of an ELISA for the detection of the native conformation of enterovirus A71. mSphere 2022; 7:e0008822 [View Article]
     [Google Scholar]
  36. Adeyemi OO, Nicol C, Stonehouse NJ, Rowlands DJ. Increasing type 1 poliovirus capsid stability by thermal selection. J Virol 2017; 91:e01586-16 [View Article] [PubMed]
     [Google Scholar]
  37. Fox H, Knowlson S, Minor PD, Macadam AJ. Genetically thermo-stabilised, immunogenic poliovirus empty capsids; a strategy for non-replicating vaccines. PLoS Pathog 2017; 13:e1006117 [View Article] [PubMed]
     [Google Scholar]
  38. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints12. Am J Hyg 1938; 27:493–497 [View Article]
     [Google Scholar]
  39. Ajito S, Iwase H, Takata S, Hirai M. Sugar-mediated stabilization of protein against chemical or thermal denaturation. J Phys Chem B 2018; 122:8685–8697 [View Article]
     [Google Scholar]
  40. Cifuente JO, Lee H, Yoder JD, Shingler KL, Carnegie MS et al. Structures of the procapsid and mature virion of enterovirus 71 strain 1095. J Virol 2013; 87:7637–7645 [View Article]
     [Google Scholar]
  41. Zhang M, Wang Y, He W, Sun Y, Guo Y et al. Design, synthesis, and evaluation of novel enterovirus 71 inhibitors as therapeutic drug leads for the treatment of human hand, foot, and mouth disease. J Med Chem 2020; 63:1233–1244 [View Article] [PubMed]
     [Google Scholar]
  42. Plevka P, Perera R, Yap ML, Cardosa J, Kuhn RJ et al. Structure of human enterovirus 71 in complex with a capsid-binding inhibitor. Proc Natl Acad Sci U S A 2013; 110:5463–5467 [View Article] [PubMed]
     [Google Scholar]
  43. Lin J, Lee LY, Roivainen M, Filman DJ, Hogle JM et al. Structure of the Fab-labeled “breathing” state of native poliovirus. J Virol 2012; 86:5959–5962 [View Article] [PubMed]
     [Google Scholar]
  44. Adeyemi OO, Sherry L, Ward JC, Pierce DM, Herod MR et al. Involvement of a Nonstructural Protein in Poliovirus Capsid Assembly. J Virol 2019; 93:e01447-18 [View Article] [PubMed]
     [Google Scholar]
  45. Kiener TK, Jia Q, Lim XF, He F, Meng T et al. Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein. Virol J 2012; 9:55 [View Article]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001771
Loading
Thermal stabilization of enterovirus A 71 and production of antigenically stabilized empty capsids
J. Gen. Virol. 103, 001771 (2022); https://doi.org/10.1099/jgv.0.001771
/content/journal/jgv/10.1099/jgv.0.001771
/content/journal/jgv/10.1099/jgv.0.001771
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error